NCT03613181: ANG1005 in Leptomeningeal Disease From Breast Cancer

NCT03613181
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 3
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Leptomeningeal Disease
Additional Notes: Patients must have documented history of brain metastasis that has been previously treated with radiation therapy
Exclusions: Patients with any prior treatment for leptomeningeal carcinomatosis, except emergency radiotherapy or shunt
https://ClinicalTrials.gov/show/NCT03613181

Comments are closed.

Up ↑